US FDA approves GSK drug for liver disease itching

The U.S. Food and Drug Administration has granted approval for GSK's new drug designed to treat severe itching associated with a specific type of liver disease. This regulatory milestone offers a new therapeutic option for patients suffering from this debilitating symptom. The approval signifies a positive development in the treatment landscape for liver disease complications. GSK's successful drug development highlights ongoing advancements in pharmaceutical research aimed at improving patient quality of life.